Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
Garrote M, López-Guerra M, García-Pagán JC, Arellano-Rodrigo E, Ferrer-Marín F, Hernández-Boluda JC, Bellosillo B, Nomdedeu M, Hernández-Gea V, Triguero A, Guijarro F, Álamo J, Baiges A, Turon F, Colomer D, Cervantes F, Alvarez-Larrán A. Garrote M, et al. Among authors: triguero a. Ann Hematol. 2024 Mar;103(3):737-747. doi: 10.1007/s00277-023-05610-x. Epub 2024 Jan 24. Ann Hematol. 2024. PMID: 38263537 Free PMC article.
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.
Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, Schecter JM, Lendvai N, Patel N, Triguero A, Ursi M. Alsdorf W, et al. Among authors: triguero a. J Comp Eff Res. 2024 Sep;13(9):e240080. doi: 10.57264/cer-2024-0080. Epub 2024 Aug 20. J Comp Eff Res. 2024. PMID: 39162049 Free PMC article. Clinical Trial.
Autoimmune biomarkers in porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology.
Cerda Reyes E, González-Navarro EA, Magaz M, Muñoz-Sánchez G, Diaz A, Silva-Junior G, Triguero A, Lafoz E, Campreciós G, Orts L, Perez-Campuzano V, Seijo S, Rubio L, Turon F, Baiges A, Hernández-Gea V, Álvarez-Larran A, Juan M, Garcia-Pagan JC. Cerda Reyes E, et al. Among authors: triguero a. Liver Int. 2021 Sep;41(9):2171-2178. doi: 10.1111/liv.14997. Epub 2021 Jul 11. Liver Int. 2021. PMID: 34173316
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A, Pedraza A, Pérez-Encinas M, Mata-Vázquez MI, Vélez P, Fox L, Gómez-Calafat M, García-Delgado R, Gasior M, Ferrer-Marín F, García-Gutiérrez V, Angona A, Gómez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernández-Boluda JC, Sanz C, Álvarez-Larrán A; On behalf of the MPN Spanish Group (GEMFIN). Triguero A, et al. Ann Hematol. 2022 Oct;101(10):2231-2239. doi: 10.1007/s00277-022-04963-z. Epub 2022 Aug 30. Ann Hematol. 2022. PMID: 36042023 Free PMC article.
Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, Guijarro F, Jiménez-Vicente C, Castillo-Girón C, Cortes A, Martínez-Roca A, Triguero A, Álamo JR, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: triguero a. Cancers (Basel). 2022 Aug 25;14(17):4107. doi: 10.3390/cancers14174107. Cancers (Basel). 2022. PMID: 36077644 Free PMC article.
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Vélez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A; On behalf of the MPN Spanish Group (GEMFIN). Triguero A, et al. Ann Hematol. 2022 Dec;101(12):2819-2820. doi: 10.1007/s00277-022-05005-4. Ann Hematol. 2022. PMID: 36264368 Free PMC article. No abstract available.
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Barbui T, et al. Among authors: triguero a. Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. Blood Cancer J. 2022. PMID: 36385103 Free PMC article. No abstract available.
Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome.
Guijarro F, López-Guerra M, Morata J, Bataller A, Paz S, Cornet-Masana JM, Banús-Mulet A, Cuesta-Casanovas L, Carbó JM, Castaño-Díez S, Jiménez-Vicente C, Cortés-Bullich A, Triguero A, Martínez-Roca A, Esteban D, Gómez-Hernando M, Álamo Moreno JR, López-Oreja I, Garrote M, Risueño RM, Tonda R, Gut I, Colomer D, Díaz-Beya M, Esteve J. Guijarro F, et al. Among authors: triguero a. Blood Adv. 2023 Oct 10;7(19):5799-5811. doi: 10.1182/bloodadvances.2023009742. Blood Adv. 2023. PMID: 37450374 Free PMC article.
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M, López-Guerra M, Arellano-Rodrigo E, Rozman M, Carbonell S, Guijarro F, Santaliestra M, Triguero A, Colomer D, Cervantes F, Álvarez-Larrán A. Garrote M, et al. Among authors: triguero a. Cancers (Basel). 2023 Jul 31;15(15):3904. doi: 10.3390/cancers15153904. Cancers (Basel). 2023. PMID: 37568719 Free PMC article.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Zambrotta GPM, Nicolini FE, Assouline S, Busque L, Pungolino E, Abruzzese E, Miggiano MC, Elena C, Alvarez-Larran A, Triguero A, Iurlo A, Bucelli C, Cerrano M, Capodanno I, Lunghi F, le Coutre P, Galimberti S, Caocci G, Maffioli M, Stagno F, Saussele S, Piazza R, Druker BJ, Fava C, Guglielmana V, Colombo F, Antolini L, Gambacorti-Passerini C. Zambrotta GPM, et al. Among authors: triguero a. Am J Hematol. 2023 Nov;98(11):1762-1771. doi: 10.1002/ajh.27073. Epub 2023 Aug 30. Am J Hematol. 2023. PMID: 37647134 Free article.
40 results